TY - JOUR
T1 - Health-related quality of life in children and adolescents with pleuropulmonary blastoma
T2 - A report from the International PPB/DICER1 Registry
AU - Nelson, Alexander T.
AU - Dybvik, Anna
AU - Mallinger, Paige
AU - Weiss McQuaid, Shelly
AU - Watson, Dave
AU - Harney, Laura A.
AU - Stewart, Douglas R.
AU - Dehner, Louis P.
AU - Messinger, Yoav H.
AU - Kunin-Batson, Alicia S.
AU - Schultz, Kris Ann P.
N1 - Publisher Copyright:
© 2022 Wiley Periodicals LLC.
PY - 2023/4
Y1 - 2023/4
N2 - Purpose: Pleuropulmonary blastoma (PPB) is the most common lung cancer of infancy and early childhood and is associated with germline DICER1 variants. Type I and Ir PPB are cystic lesions treated surgically, with a subset of children with type I receiving chemotherapy. Type II and III are more aggressive lesions, treated with surgery, intensive chemotherapy and potentially radiation. We sought to assess health-related quality of life (HRQoL) in children with PPB and known germline DICER1 variants. Methods: Children with a diagnosis of PPB or germline DICER1 pathogenic variant without history of PPB or other DICER1-related neoplasm (DICER1+ only) were enrolled in the International PPB/DICER1 Registry. Parent reports for participants aged 2–17 years for the PedsQL v.4 and PedsQL Multidimensional Fatigue Scale v.3 were collected. Fatigue, physical, and psychosocial function scores were compared. Results: Analysis included 84 participants (PPB type Ir = 20, type I = 15, type II/III = 27, DICER1+ only = 22). Total fatigue scores of participants with type I and II/III PPB were lower compared to DICER1+ only, with effect size larger in type II/III (−0.82 vs. −0.40). Total psychosocial and physical functioning scores were lower in participants with type I and type II/III PPB compared to DICER1+ only, with larger effects noted in type II/III. Female sex was suggestive of worse HRQoL for both type I/Ir and type II/III cohorts. Conclusions: These data demonstrate the importance of regular HRQoL assessment in patients with a history of PPB as well as the importance and feasibility of studying HRQoL in children with rare tumors.
AB - Purpose: Pleuropulmonary blastoma (PPB) is the most common lung cancer of infancy and early childhood and is associated with germline DICER1 variants. Type I and Ir PPB are cystic lesions treated surgically, with a subset of children with type I receiving chemotherapy. Type II and III are more aggressive lesions, treated with surgery, intensive chemotherapy and potentially radiation. We sought to assess health-related quality of life (HRQoL) in children with PPB and known germline DICER1 variants. Methods: Children with a diagnosis of PPB or germline DICER1 pathogenic variant without history of PPB or other DICER1-related neoplasm (DICER1+ only) were enrolled in the International PPB/DICER1 Registry. Parent reports for participants aged 2–17 years for the PedsQL v.4 and PedsQL Multidimensional Fatigue Scale v.3 were collected. Fatigue, physical, and psychosocial function scores were compared. Results: Analysis included 84 participants (PPB type Ir = 20, type I = 15, type II/III = 27, DICER1+ only = 22). Total fatigue scores of participants with type I and II/III PPB were lower compared to DICER1+ only, with effect size larger in type II/III (−0.82 vs. −0.40). Total psychosocial and physical functioning scores were lower in participants with type I and type II/III PPB compared to DICER1+ only, with larger effects noted in type II/III. Female sex was suggestive of worse HRQoL for both type I/Ir and type II/III cohorts. Conclusions: These data demonstrate the importance of regular HRQoL assessment in patients with a history of PPB as well as the importance and feasibility of studying HRQoL in children with rare tumors.
KW - DICER1
KW - DICER1 tumor predisposition
KW - Health-Related Quality of Life
KW - PedsQL
KW - Pleuropulmonary Blastoma
UR - https://www.scopus.com/pages/publications/85143398644
U2 - 10.1002/pbc.30077
DO - 10.1002/pbc.30077
M3 - Article
C2 - 36424733
AN - SCOPUS:85143398644
SN - 1545-5009
VL - 70
JO - Pediatric Blood and Cancer
JF - Pediatric Blood and Cancer
IS - 4
M1 - e30077
ER -